查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1988030

慢性脫髓鞘多發性神經炎市場：治療方法、患者年齡、疾病嚴重程度、最終用戶和通路分類－2026-2032年全球市場預測

Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment Modality, Patient Age, Disease Severity, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，慢性脫髓鞘多發性神經炎(CIDP) 市場價值將達到 26.4 億美元，到 2026 年將成長至 28 億美元，到 2032 年將達到 39.6 億美元，複合年成長率為 5.97%。

主要市場統計數據
基準年 2025 26.4億美元
預計年份：2026年 28億美元
預測年份 2032 39.6億美元
複合年成長率 (%) 5.97%

它簡潔地組織了臨床複雜性、治療路徑和策略重點，指導護理、研究和商業化領域的相關人員做出明智的決策。

慢性脫髓鞘多發性神經炎在臨床、診斷和治療方面具有獨特的複雜性，需要綜合分析以製定策略決策。本執行摘要整合了關於該疾病的生物學特徵、診療路徑、治療方法和商業格局的最新知識，為臨床醫生、保險公司和相關人員提供簡潔全面的概述。摘要闡述了不斷發展的診斷標準、免疫療法的進展以及變革性的醫療服務模式如何相互交織並影響患者預後和服務利用。

診斷技術的進步、治療方法的創新以及醫療保健服務系統的重新設計如何匯聚在一起，重新定義治療方法和患者管理中的價值評估。

慢性脫髓鞘多發性神經炎的治療管理格局正在經歷一場變革，這主要得益於技術進步、監管規範的完善以及患者期望的不斷變化。新的診斷方法和生物標記研究正在改善病例識別和預後分層，從而實現更具針對性的治療策略。同時，免疫球蛋白製劑和給藥方法的進步，以及單株抗體和其他免疫調節劑應用經驗的積累，正在拓展臨床醫生的選擇範圍，並促使人們重新評估長期治療通訊協定。

評估關稅政策對供應鏈、製造策略和治療可用性的影響，並考慮其對採購和臨床決策的影響。

貿易和關稅政策的趨勢可能對用於治療慢性脫髓鞘多發性神經炎的療法的生產經濟性、供應鏈韌性和成本結構產生重大影響。原料和成品生技藥品的進口關稅和監管要求的變化可能會使上游採購流程複雜化，並促使製造商重新評估其供應商網路和庫存策略。同時，關稅可能會改變生產的地域經濟格局，並促使製造地遷移或採用雙重採購安排，以減輕貿易中斷的影響。

將治療方法特徵、醫療保健環境、通路、年齡層和嚴重程度與臨床和營運決策框架聯繫起來的詳細細分分析。

基於細分市場的分析揭示了不同治療方法、醫療機構、配送機制、患者年齡層和疾病嚴重程度類別所面臨的運作和臨床挑戰。依治療方法分析，治療方案包括皮質類固醇、Azathioprine、Cyclophosphamide、Mycophenolate Mofetil和Rituximab單抗等免疫抑制劑，以及靜脈注射免疫球蛋白、血漿置換和皮下注射免疫球蛋白。每種療法都有其獨特的給藥需求、監測需求和安全性特徵，這些因素會影響醫療機構的選擇和資源分配。在此背景下，不同類型的免疫抑制劑需要專門的監測通訊協定和病患諮詢，這會影響專科診所與綜合醫院的用藥模式。

影響治療方案取得、報銷和提供的全球主要區域的相對區域趨勢和策略考量。

區域趨勢影響著美洲、歐洲、中東和非洲以及亞太市場的臨床實踐模式、法規環境、報銷框架和供應物流。在美洲，不斷發展的支付模式和健全的專科醫療網路支持著以門診輸液服務和居家給藥（在臨床適宜的情況下）為重點。同時，生物製藥和免疫療法的監管細則正在推動給藥平台的創新。相較之下，歐洲和中東及非洲部分地區的准入和報銷情況存在差異，需要製定在地化的策略，並考慮國家處方藥目錄、集中採購和區域生產夥伴關係。

製造商和服務供應商在協調臨床證據、供應物流和患者支援以實現永續成長方面面臨競爭與合作的挑戰。

競爭情報顯示，眾多機構在該治療領域開展業務，從生產免疫球蛋白製劑的生物製藥企業到提供血漿置換和家庭輸液服務的專業服務供應商，不一而足。擁有臨床開發專長和完善的生產及分銷基礎設施的公司，更有能力滿足生物製藥固有的複雜低溫運輸和品管要求。此外，投資於病患支援計畫、居家照護護理師培訓以及支持用藥依從性的數位化工具的公司，可以提升其對支付方和醫療服務提供者的價值提案。

為高階主管提供切實可行的策略措施，以加強證據產生、鞏固供應鏈並推動醫療保健服務，從而維持臨床和商業性的成功。

產業領導者應採取多管齊下的策略，整合臨床證據的發展、供應鏈韌性以及相關人員的協作，以最大限度地提高治療效果和業務永續性。首先，他們應優先創建可靠的真實世界數據 (RWE) 和開展有針對性的臨床試驗，以揭示長期療效、治療方法之間的療效比較以及能夠引起支付方共鳴的成本效益指標。其次，他們應透過多元化關鍵原料來源、建立區域性生產或填充/包裝能力以及協商靈活的物流安排來增強供應鏈韌性，從而降低關稅和貿易風險。

透過透明、多方面的研究途徑，結合專家訪談、系統性文獻綜述和迭代檢驗，我們得出實用的臨床和操作見解。

本分析的調查方法結合了定性專家對話、嚴謹的原始文獻回顧以及對營運和監管趨勢的系統性整合。關鍵資訊來源包括對臨床專業人員、藥房負責人和醫療系統管理人員的訪談，以了解他們對治療方法選擇、靜脈給藥能力和患者管理的實際觀點。除這些訪談外，對同行評審的臨床研究、監管指南和專業學會建議的系統性回顧，確保了治療和診斷趨勢均基於檢驗的證據。

透過整合臨床趨勢、營運挑戰和策略優勢，我們制定了一條改善患者預後和永續醫療保健服務的道路。

本執行摘要對影響慢性脫髓鞘多發性神經炎治療的臨床、運作和策略因素進行了全面闡述。報告重點強調了向個人化免疫調節策略的轉變、對居家和門診護理模式日益重視，以及真實世界數據（REW）在支持與支付方合作方面的重要性日益凸顯。分析還著重探討了可能影響治療方法可及性和選擇的供應鏈因素和政策主導壓力，強調了製定積極主動的緊急時應對計畫和加強相關人員合作的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：慢性脫髓鞘多發性神經炎市場（依治療方法）

  • 皮質類固醇
  • 免疫抑制劑
    • Azathioprine
    • Cyclophosphamide
    • Mycophenolate Mofetil
    • Rituximab
  • 靜脈注射免疫球蛋白
  • 血漿置換
  • 皮下注射免疫球蛋白

第9章 依患者年齡分類的慢性脫髓鞘多發性神經炎市場

  • 成人版
  • 老年人
  • 兒童

第10章：慢性脫髓鞘多發性神經炎－以嚴重程度分類的疾病市場

  • 溫和的
  • 緩和
  • 嚴重

第11章：慢性脫髓鞘多發性神經炎市場：以最終用戶分類

  • 居家照護
  • 醫院
  • 專科診所

第12章：慢性脫髓鞘多發性神經炎市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：慢性脫髓鞘多發性神經炎市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章慢性脫髓鞘多發性神經炎市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：慢性脫髓鞘多發性神經炎市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國慢性脫髓鞘多發性神經炎市場

第17章：中國慢性脫髓鞘多發性神經炎市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Avalon Pharma Pvt Ltd.
  • Baxter International, Inc.
  • Biotest AG
  • CSL Limited
  • F. Hoffmann-La Roche Ltd.
  • Green Cross Corporation
  • Grifols, SA
  • Johnson & Johnson Services, Inc.
  • Kedrion Biopharma
  • Lee BioSolutions
  • Merck & Co., Inc.
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Viatris Inc.
  • Zai Lab Limited
Product Code: MRR-F97DD5A7D581

The Chronic Inflammatory Demyelinating Polyneuropathy Market was valued at USD 2.64 billion in 2025 and is projected to grow to USD 2.80 billion in 2026, with a CAGR of 5.97%, reaching USD 3.96 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.64 billion
Estimated Year [2026] USD 2.80 billion
Forecast Year [2032] USD 3.96 billion
CAGR (%) 5.97%

Concise framing of clinical complexity, treatment pathways, and strategic priorities to orient stakeholders toward informed decisions across care, research, and commercialization

Chronic inflammatory demyelinating polyneuropathy presents distinct clinical, diagnostic, and therapeutic complexities that demand integrated analysis for strategic decision making. This executive summary synthesizes current understanding of disease biology, care pathways, therapeutic modalities, and the commercial environment to equip clinicians, payers, and industry stakeholders with a concise yet comprehensive briefing. It addresses how evolving diagnostic criteria, advances in immunotherapy, and shifts in care delivery intersect to influence patient journeys and service utilization.

By focusing on evidence-based treatment practices and operational realities across settings of care, the narrative connects clinical endpoints with real-world considerations such as treatment tolerability, infusion infrastructure, and the capacity of specialty clinics and home care services. Moreover, the introduction frames emerging clinical trial trends and regulatory approaches that are reshaping the competitive landscape. Ultimately, this section sets the stage for a deeper exploration of transformative shifts, tariff implications, segmentation intelligence, regional dynamics, and actionable recommendations crafted for executives and clinical leaders tasked with navigating a complex, rapidly changing field.

How diagnostic advances, treatment innovation, and care delivery redesign are converging to redefine therapeutic approaches and value assessment in patient management

The landscape for managing chronic inflammatory demyelinating polyneuropathy is undergoing transformative shifts driven by technological maturation, regulatory refinement, and evolving patient expectations. Novel diagnostics and biomarker research are improving case ascertainment and prognostic stratification, which in turn support more targeted therapeutic strategies. Concurrently, advances in the formulation and delivery of immunoglobulin therapies, alongside growing experience with monoclonal antibodies and other immunomodulatory agents, are expanding clinician options and prompting reassessment of long-term management protocols.

At the same time, health systems are adjusting care delivery models to emphasize outpatient and home-based administration where clinically appropriate. This shift is facilitated by advancements in subcutaneous immunoglobulin formulations and remote monitoring technologies, which reduce reliance on inpatient infusion centers and enhance patient convenience. Transitional dynamics also include payer scrutiny around long-term therapy value, leading to more rigorous outcomes measurement and utilization management. Collectively, these forces are accelerating a move toward personalized, value-oriented care that recognizes both clinical efficacy and system sustainability.

Assessment of tariff policy effects on supply chains, manufacturing strategies, and treatment availability with implications for procurement and clinical decision making

Policy developments in trade and tariffs can exert significant influence on manufacturing economics, supply chain resilience, and the cost structure of therapies used in chronic inflammatory demyelinating polyneuropathy care. Changes to import duties or regulatory requirements for raw materials and finished biologics may increase upstream sourcing complexity, prompting manufacturers to reassess supplier networks and inventory strategies. In parallel, tariffs can shift the geographic economics of production, encouraging relocation of manufacturing nodes or the adoption of dual-sourcing arrangements to mitigate exposure to trade disruptions.

These dynamics can cascade into downstream stakeholders: hospital pharmacies, specialty clinics, and distribution channels may face altered procurement lead times or pricing pressures that necessitate adjustments in contracting and inventory management. Clinicians and health systems may experience variability in product availability, which could influence therapeutic choices between intravenous and subcutaneous formulations where multiple options exist. Consequently, strategic planning must incorporate scenario analysis of tariff impacts on supply continuity, cost of goods, and the operational feasibility of home care versus facility-based administration, while also engaging with payers to align reimbursement models with emerging cost structures.

In-depth segmentation analysis linking therapy characteristics, care settings, distribution pathways, age cohorts, and severity gradations to clinical and operational decision frameworks

Segment-specific analysis reveals differentiated operational and clinical imperatives across treatment modalities, care settings, distribution mechanisms, patient age groups, and disease severity categories. When examined by treatment modality, the therapeutic mix spans corticosteroids, immunosuppressants - including azathioprine, cyclophosphamide, mycophenolate mofetil, and rituximab - intravenous immunoglobulin, plasma exchange, and subcutaneous immunoglobulin, each with distinct administration requirements, monitoring needs, and safety profiles that influence site selection and resource allocation. In this context, immunosuppressant subtypes demand specialized monitoring protocols and patient counseling that can shape utilization patterns in specialty clinics compared with broader hospital settings.

End-user segmentation highlights the operational tradeoffs between home care, hospitals, and specialty clinics. Home care models prioritize patient education, device compatibility, and remote monitoring, while hospitals underscore infusion capacity and acute management capabilities. Specialty clinics often serve as hubs for diagnostic clarification and initiation of long-term immunotherapy. Distribution channel differentiation across hospital pharmacy, online pharmacy, and retail pharmacy affects dispensing practices, cold chain stewardship, and patient access. Patient age segmentation into adult, geriatric, and pediatric populations underscores differing safety considerations, dosing strategies, and caregiver support needs that must be integrated into treatment planning. Disease severity segmentation - mild, moderate, and severe - further informs therapeutic sequencing, frequency of interventions, and intensity of monitoring, creating decision pathways that intersect with payer authorization and care coordination requirements.

Comparative regional dynamics and strategic considerations across major global territories shaping access, reimbursement, and delivery of therapeutic options

Regional dynamics shape clinical practice patterns, regulatory environments, reimbursement frameworks, and supply logistics across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, evolving payer models and robust specialty care networks support a focus on outpatient infusion services and home administration where clinically appropriate, while regulatory clarity around biologics and immunotherapies encourages innovation in delivery platforms. Conversely, certain jurisdictions in Europe, the Middle East, and Africa exhibit heterogeneity in access and reimbursement, prompting localized strategies that account for national formularies, centralized procurement, and regional manufacturing partnerships.

In the Asia-Pacific region, rapid growth in healthcare infrastructure and an expanding base of specialist clinicians are creating opportunities for broader access to advanced therapies, though variability in regulatory pathways and local manufacturing capacity remains a factor. Across these regions, transitions toward value-based procurement and a greater emphasis on real-world evidence are influencing formulary decisions and clinical guidelines. Therefore, market entrants and established suppliers must calibrate commercialization strategies to local regulatory, payer, and delivery realities, while also coordinating cross-regional supply chain and medical affairs efforts to ensure consistent standards of care.

Competitive and collaborative imperatives for manufacturers and service providers to align clinical evidence, supply logistics, and patient support for sustainable growth

Competitive intelligence indicates that a diverse set of organizations - from biopharmaceutical manufacturers producing immunoglobulin formulations to specialty service providers delivering plasma exchange and home infusion capabilities - are active in this therapeutic area. Firms that combine clinical development expertise with robust manufacturing and distribution infrastructures are better positioned to meet the complex cold chain and quality control demands inherent to biologic therapies. In addition, entities that invest in patient support programs, training for home care nurses, and digital adherence tools strengthen their value proposition to payers and providers.

Partnerships between pharmaceutical companies and logistics providers, as well as collaborations with academic centers for post-marketing evidence generation, are becoming more common. These alliances support lifecycle management strategies and help build the real-world datasets that payers increasingly require. Service providers that offer scalable infusion capacity and streamlined prior authorization support gain traction with clinicians seeking to minimize administrative burden. Overall, organizations that align clinical evidence generation with operational excellence and stakeholder engagement are likely to sustain competitive advantage as treatment paradigms evolve.

Practical strategic measures for executives to enhance evidence generation, fortify supply chains, and advance care delivery to sustain clinical and commercial success

Industry leaders should pursue a multipronged strategy that integrates clinical evidence development, supply chain resilience, and stakeholder engagement to maximize therapeutic impact and operational sustainability. First, prioritize generation of robust real-world evidence and targeted clinical studies that clarify long-term outcomes, comparative effectiveness across modalities, and cost-utility measures that resonate with payers. Second, strengthen supply chain resilience by diversifying sourcing of critical raw materials, establishing regional manufacturing or fill-finish capabilities, and negotiating flexible logistics arrangements to mitigate tariff and trade risks.

Third, invest in care delivery innovations that expand safe home administration and support specialty clinics through training, telehealth integration, and digital monitoring tools to improve adherence and reduce total cost of care. Fourth, engage proactively with payers and policy makers to align reimbursement pathways with clinical value, leveraging outcomes data and patient-reported measures. Finally, cultivate cross-sector partnerships - including with academic institutions and patient advocacy groups - to accelerate guideline adoption, improve patient education, and ensure equitable access across age cohorts and severity profiles. Together, these actions create a resilient commercial model grounded in clinical credibility and operational adaptability.

Transparent, multi-source research approach combining expert interviews, systematic literature review, and iterative validation to produce actionable clinical and operational insights

The research methodology underpinning this analysis combines qualitative expert engagement, rigorous review of primary literature, and structured synthesis of operational and regulatory developments. Primary inputs included consultations with clinical specialists, pharmacy leaders, and health system administrators to capture frontline perspectives on treatment selection, infusion capacity, and patient management. These interviews were complemented by a systematic review of peer-reviewed clinical studies, regulatory guidance, and professional society recommendations to ensure that therapeutic and diagnostic trends are grounded in validated evidence.

To ensure reliability, findings were triangulated across multiple sources and validated through iterative expert review. Attention was given to distinguishing established clinical practice from emerging experimental approaches, and to identifying gaps in evidence where further research is warranted. Limitations are acknowledged: regional heterogeneity in clinical guidelines and the variable quality of real-world datasets can constrain the generalizability of certain operational inferences. Nonetheless, the methodology emphasizes transparency, reproducibility, and the practical applicability of insights for decision-makers in clinical, commercial, and policy roles.

Synthesis of clinical trends, operational challenges, and strategic levers that together define the pathway to improved patient outcomes and sustainable care delivery

This executive synthesis delivers a cohesive view of the clinical, operational, and strategic forces shaping care for chronic inflammatory demyelinating polyneuropathy. It underscores a shift toward personalized immunomodulatory strategies, increasing emphasis on home and outpatient delivery models, and the rising importance of real-world evidence to support payer engagement. The analysis also highlights supply chain considerations and policy-driven pressures that can influence availability and selection of therapies, reinforcing the need for proactive contingency planning and stakeholder alignment.

In closing, effective responses require coordinated action across evidence generation, supply operations, and payer engagement to ensure that patients receive timely, appropriate care while health systems manage cost and capacity. Stakeholders who integrate clinical insight with pragmatic operational strategies will be better positioned to navigate uncertainty and to translate scientific advances into improved outcomes for patients living with this chronic neurologic condition.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment Modality

  • 8.1. Corticosteroids
  • 8.2. Immunosuppressants
    • 8.2.1. Azathioprine
    • 8.2.2. Cyclophosphamide
    • 8.2.3. Mycophenolate Mofetil
    • 8.2.4. Rituximab
  • 8.3. Intravenous Immunoglobulin
  • 8.4. Plasma Exchange
  • 8.5. Subcutaneous Immunoglobulin

9. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Patient Age

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Disease Severity

  • 10.1. Mild
  • 10.2. Moderate
  • 10.3. Severe

11. Chronic Inflammatory Demyelinating Polyneuropathy Market, by End User

  • 11.1. Home Care
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Chronic Inflammatory Demyelinating Polyneuropathy Market

17. China Chronic Inflammatory Demyelinating Polyneuropathy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Avalon Pharma Pvt Ltd.
  • 18.6. Baxter International, Inc.
  • 18.7. Biotest AG
  • 18.8. CSL Limited
  • 18.9. F. Hoffmann-La Roche Ltd.
  • 18.10. Green Cross Corporation
  • 18.11. Grifols, S.A.
  • 18.12. Johnson & Johnson Services, Inc.
  • 18.13. Kedrion Biopharma
  • 18.14. Lee BioSolutions
  • 18.15. Merck & Co., Inc.
  • 18.16. Novartis AG
  • 18.17. Octapharma AG
  • 18.18. Pfizer Inc.
  • 18.19. Sanofi SA
  • 18.20. Takeda Pharmaceutical Company Limited
  • 18.21. Teva Pharmaceutical Industries Ltd.
  • 18.22. UCB S.A.
  • 18.23. Viatris Inc.
  • 18.24. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 139. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 140. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 161. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 166. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 167. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 169. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)